vs
PATHWARD FINANCIAL, INC.（CASH）与MIMEDX GROUP, INC.（MDXG）财务数据对比。点击上方公司名可切换其他公司
PATHWARD FINANCIAL, INC.的季度营收约是MIMEDX GROUP, INC.的2.3倍（$276.3M vs $118.1M），PATHWARD FINANCIAL, INC.净利率更高（26.4% vs 12.9%，领先13.5%），过去两年PATHWARD FINANCIAL, INC.的营收复合增速更高（21.0% vs 18.1%）
Pathward Financial, Inc.是一家总部位于美国的银行及金融服务企业，其前身为Meta金融集团旗下相关业务主体，2022年母公司将“Meta”商标出售给Meta Platforms后，正式启用现有名称。
MiMedx是一家总部位于美国佐治亚州玛丽埃塔的生物医疗企业，成立于2008年。该企业以胎盘、羊膜囊、脐带等分娩组织为原料，开发可用于植皮手术的医用真皮产品，在生物再生医疗领域开展业务。
CASH vs MDXG — 直观对比
营收规模更大
CASH
是对方的2.3倍
$118.1M
净利率更高
CASH
高出13.5%
12.9%
两年增速更快
CASH
近两年复合增速
18.1%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $276.3M | $118.1M |
| 净利润 | $72.9M | $15.2M |
| 毛利率 | — | 83.9% |
| 营业利润率 | — | 17.8% |
| 净利率 | 26.4% | 12.9% |
| 营收同比 | — | 27.1% |
| 净利润同比 | — | 104.2% |
| 每股收益（稀释后） | $3.35 | $0.10 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CASHMDXG
| Q1 26 | $276.3M | — | ||
| Q4 25 | $173.1M | $118.1M | ||
| Q3 25 | $186.7M | $113.7M | ||
| Q2 25 | $195.8M | $98.6M | ||
| Q1 25 | $274.8M | $88.2M | ||
| Q4 24 | $182.6M | $92.9M | ||
| Q3 24 | $179.5M | $84.1M | ||
| Q2 24 | $188.6M | $87.2M |
净利润CASHMDXG
| Q1 26 | $72.9M | — | ||
| Q4 25 | $35.2M | $15.2M | ||
| Q3 25 | $38.8M | $16.7M | ||
| Q2 25 | $42.1M | $9.6M | ||
| Q1 25 | $75.0M | $7.0M | ||
| Q4 24 | $30.0M | $7.4M | ||
| Q3 24 | $33.5M | $8.1M | ||
| Q2 24 | $44.9M | $17.6M |
毛利率CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | — | 83.9% | ||
| Q3 25 | — | 83.5% | ||
| Q2 25 | — | 81.1% | ||
| Q1 25 | — | 81.2% | ||
| Q4 24 | — | 81.8% | ||
| Q3 24 | — | 81.8% | ||
| Q2 24 | — | 83.0% |
营业利润率CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | 24.6% | 17.8% | ||
| Q3 25 | 25.9% | 19.5% | ||
| Q2 25 | 24.1% | 12.5% | ||
| Q1 25 | 33.2% | 9.4% | ||
| Q4 24 | 19.8% | 11.9% | ||
| Q3 24 | 20.9% | 13.3% | ||
| Q2 24 | 27.1% | 26.9% |
净利率CASHMDXG
| Q1 26 | 26.4% | — | ||
| Q4 25 | 20.3% | 12.9% | ||
| Q3 25 | 20.8% | 14.7% | ||
| Q2 25 | 21.5% | 9.8% | ||
| Q1 25 | 27.3% | 8.0% | ||
| Q4 24 | 16.4% | 8.0% | ||
| Q3 24 | 18.7% | 9.6% | ||
| Q2 24 | 23.8% | 20.2% |
每股收益（稀释后）CASHMDXG
| Q1 26 | $3.35 | — | ||
| Q4 25 | $1.57 | $0.10 | ||
| Q3 25 | $1.69 | $0.11 | ||
| Q2 25 | $1.81 | $0.06 | ||
| Q1 25 | $3.14 | $0.05 | ||
| Q4 24 | $1.23 | $0.05 | ||
| Q3 24 | $1.34 | $0.05 | ||
| Q2 24 | $1.78 | $0.12 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $157.6M | $166.1M |
| 总债务越低越好 | $59.5M | $18.0M |
| 股东权益账面价值 | $850.7M | $256.5M |
| 总资产 | $7.1B | $342.7M |
| 负债/权益比越低杠杆越低 | 0.07× | 0.07× |
8季度趋势，按日历期对齐
现金及短期投资CASHMDXG
| Q1 26 | $157.6M | — | ||
| Q4 25 | $331.2M | $166.1M | ||
| Q3 25 | $120.6M | $142.1M | ||
| Q2 25 | $258.3M | $118.9M | ||
| Q1 25 | $254.2M | $106.4M | ||
| Q4 24 | $597.4M | $104.4M | ||
| Q3 24 | $158.3M | $88.8M | ||
| Q2 24 | $298.9M | $69.0M |
总债务CASHMDXG
| Q1 26 | $59.5M | — | ||
| Q4 25 | $33.5M | $18.0M | ||
| Q3 25 | $33.5M | — | ||
| Q2 25 | $33.4M | — | ||
| Q1 25 | $33.4M | — | ||
| Q4 24 | $33.4M | $19.0M | ||
| Q3 24 | $33.4M | — | ||
| Q2 24 | $33.3M | — |
股东权益CASHMDXG
| Q1 26 | $850.7M | — | ||
| Q4 25 | $854.5M | $256.5M | ||
| Q3 25 | $858.0M | $238.9M | ||
| Q2 25 | $819.0M | $216.6M | ||
| Q1 25 | $814.7M | $202.8M | ||
| Q4 24 | $758.3M | $193.1M | ||
| Q3 24 | $822.5M | $181.0M | ||
| Q2 24 | $748.4M | $168.0M |
总资产CASHMDXG
| Q1 26 | $7.1B | — | ||
| Q4 25 | $7.6B | $342.7M | ||
| Q3 25 | $7.2B | $319.0M | ||
| Q2 25 | $7.2B | $291.1M | ||
| Q1 25 | $7.0B | $270.4M | ||
| Q4 24 | $7.6B | $263.9M | ||
| Q3 24 | $7.5B | $243.9M | ||
| Q2 24 | $7.5B | $230.2M |
负债/权益比CASHMDXG
| Q1 26 | 0.07× | — | ||
| Q4 25 | 0.04× | 0.07× | ||
| Q3 25 | 0.04× | — | ||
| Q2 25 | 0.04× | — | ||
| Q1 25 | 0.04× | — | ||
| Q4 24 | 0.04× | 0.10× | ||
| Q3 24 | 0.04× | — | ||
| Q2 24 | 0.04× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $25.0M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | 1.64× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | $108.3M | $25.0M | ||
| Q3 25 | $303.7M | $29.3M | ||
| Q2 25 | $30.4M | $14.4M | ||
| Q1 25 | $188.3M | $5.3M | ||
| Q4 24 | $-71.7M | $18.8M | ||
| Q3 24 | $143.1M | $19.6M | ||
| Q2 24 | $113.2M | $21.8M |
自由现金流CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | $104.1M | — | ||
| Q3 25 | $300.3M | — | ||
| Q2 25 | $27.7M | — | ||
| Q1 25 | $184.7M | — | ||
| Q4 24 | $-73.8M | — | ||
| Q3 24 | $138.8M | — | ||
| Q2 24 | $111.0M | — |
自由现金流率CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | 60.1% | — | ||
| Q3 25 | 160.9% | — | ||
| Q2 25 | 14.1% | — | ||
| Q1 25 | 67.2% | — | ||
| Q4 24 | -40.4% | — | ||
| Q3 24 | 77.3% | — | ||
| Q2 24 | 58.8% | — |
资本支出强度CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | 2.4% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.4% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.2% | — |
现金转化率CASHMDXG
| Q1 26 | — | — | ||
| Q4 25 | 3.08× | 1.64× | ||
| Q3 25 | 7.83× | 1.75× | ||
| Q2 25 | 0.72× | 1.50× | ||
| Q1 25 | 2.51× | 0.75× | ||
| Q4 24 | -2.39× | 2.53× | ||
| Q3 24 | 4.27× | 2.42× | ||
| Q2 24 | 2.52× | 1.24× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CASH
| Noninterest Income | $151.2M | 55% |
| Net Interest Income | $125.1M | 45% |
MDXG
| Wound | $78.7M | 67% |
| Surgical | $39.4M | 33% |
